Isofol Medical AB (publ) (STO:ISOFOL)

Market Cap	214.73M -26.1%
Revenue (ttm)	n/a
Net Income	-54.17M
EPS	-0.25
Shares Out	320.49M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	190,807
Average Volume	994,547
Open	0.6750
Previous Close	0.6700
Day's Range	0.6670 - 0.6900
52-Week Range	0.5515 - 2.1960
Beta	0.87
RSI	46.39
Earnings Date	May 19, 2026

About Isofol Medical AB

Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 6
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ISOFOL